Preparing a grant application?
Can CQUEST help with any PROMs component?
Drop in for a chat today, and we can provide advice on the spot!
utsmeet.zoom.us/j/8335777658…
Planning a grant submission and need some PROM advice? Drop-in for a chat today at 10 AM AEST!
utsmeet.zoom.us/j/8335777658…
📢 Applications are now open for ANZGOG's 2026 Fund for New Research Grants.
The next breakthrough in gynaecological cancer treatment, prevention, or care could start with a research question waiting to be answered.
ANZGOG is pleased to open applications for the 2026 Fund for New Research Grant Program, supporting researchers to explore innovative ideas and generate the evidence needed to progress larger studies and future clinical trials.
Thanks to the generosity of ANZGOG donors, funding is available across four priority research areas:
🔹 Endometrial cancer focused surgical study – up to $55,000
🔹 Leiomyosarcoma focused project – $65,000
🔹 Endometrial cancer focused project – up to $100,000
🔹 Clinical or pre-clinical ovarian carcinosarcoma project – up to $50,000
These grants are designed to support early-stage research, helping investigators test promising concepts and build the foundations for future discoveries that improve outcomes for people affected by gynaecological cancers.
Learn more and apply: anzgog.org.au/research/fund-…
#GynaecologicalCancer #CancerResearch #ResearchFunding
CQUEST retweeted
Applications for the First Nations Cancer Scholarship close on 11/09.
Indigenous students engaged in full-time postgraduate studies or research within a cancer-related field covering health, research, or policy are eligible. Learn more: bit.ly/4en2NzR
@AuroraEducation
CQUEST retweeted
Cancer Australia is calling for applications for the First Nations Cancer Scholarship - a dedicated funding for Aboriginal & Torres Strait Islander students, health professionals and researchers in the field of cancer.
Learn more: bit.ly/4en2NzR @AuroraEducation
CQUEST retweeted
🔍 New @EORTC #QualityofLife publication.
The new EORTC QLQ‑VU34 was developed to assess quality of life in women with vulva cancer.
Cross-cultural testing in 9 countries showed high relevance, acceptability & comprehensiveness.
🔗 eortc.org/publications/
#GivingVoice2Patients
Setting the record straight on EQ-5D nomenclature 📣
EQ-5D is not an abbreviation. It's the correct term when referencing all four versions of the instrument. This means their names should not be spelt out as this is inaccurate.
Learn more 👉 bit.ly/3PQbclO
#PROMs

ALT Correct naming of EQ-5D instruments is shown on the left: EQ-5D-3L, EQ-5D-5L, EQ-5D-Y-3L, EQ-5D-Y-5L, each with a checkmark. Examples of Incorrect naming is on the right: EuroQol-5D-3 Level, European Quality of Life Five Dimension, EQ5D-Y-3L, EuroQol 5-Dimension Youth 5-Level, each with an X mark. EuroQol logo is at the bottom right.
CQUEST retweeted
We're proud to share our 2025 Annual Research Report, which showcases a year of significant trial milestones, forging international partnerships, new grant funding and deeper consumer engagement to drive meaningful research to improve cancer outcomes.
ap1.hubs.ly/y0YF8b0
CQUEST retweeted
The wait is almost over! The @ANZUPTrials #ANZUP26 ASM is coming to #Adelaide in just under 2 weeks' time! View the program here: anzup.org.au/asm-program/. It's not too late to register: anzup.org.au/asm-registratio… @BizEventsAdl @AdelaideCC @DrCraigGedye @LisaButler5 @Prof_IanD
CQUEST retweeted
Have a melanoma or skin cancer research idea? 🔬
Submit your concept to be developed at our MASC Trials workshop & receive expert feedback.
📅 25 June, 9am – 1pm
👉 Register ow.ly/Nzta50Z6uE5
📧 Submit: [email protected]
#MelanomaResearch #SkinCancer #ClinicalTrials
Reminder: one month remains to submit to QLR's special issue, "Quality of life in people with mental disorders – beyond global scores." Learn more at buff.ly/WEOrYmH
CQUEST retweeted
Early bird registrations for the 2026 TOGA ASM extended until 8 June!
Don’t miss your opportunity to attend one of Australia’s leading thoracic oncology meetings at discounted rates.
✔ Outstanding scientific program
✔ International and local experts
June is Uterine Cancer Awareness Month, and the picture across Australia and Aotearoa New Zealand cannot be ignored.
Uterine cancers are the most common and fastest rising gynaecological cancers in Australia and Aotearoa New Zealand. And most women have never heard of it.
Around 12 women across both countries will hear those words today. More than two will lose their lives.
Yet 94% of women report they were unaware of uterine cancer. It is unknown, underfunded, and unsupported. Uterine cancers are the poorest funded cancer in terms of research funding, both in absolute terms and in terms of disease burden.
That has to change. Our State of the Nation report sets out what we know and what must be done. Read it here: anzgog.org.au/state-of-the-n…
@CancerAustralia #UCAM #UterineCancer #EndometrialCancer #AdvancingResearchSavingLives
CQUEST retweeted
iPrevent is an evidence-based online tool designed to help women better understand their individual breast cancer risk and learn what actions may help reduce it.
Learn more:
breastcancertrials.org.au/br…
📢CCTG Members - we've extended the deadline!
Submissions now closing, Monday 18 May 2026 at 9 AM AEST.
Feel free to get in touch with our team if you'd like to discuss an idea for submission: [email protected].
Application & guidelines: bit.ly/3OMBkgO
CQUEST retweeted
Registrations are open for the TOGA 2026 ASM!
Take advantage of discounted rates - early bird closed May 31 2026.
📅 Dates: July 15-17
📍 Location: Pullman Melbourne Albert Park
Register now > buff.ly/0CgXhZ5
CQUEST retweeted
Are you coming to the #ANZUP26 ASM in #Adelaide this June? @ANZUPTrials have partnered with @Qantas to offer special flight discounts. Read more on our website: anzup.org.au/asm-registratio… @BizEventsAdl @AdelaideCC
📢CCTG Members - applications are now open!
💰 Up to $20,000 AUD
✅ for two cancer-related QoL activities
🗓️ 12-month period
🤝 CQUEST support & guidance
For more info & to apply, scan the QR code or click here: bit.ly/3OMBkgO




























